



**C4X Discovery Holdings plc**  
("C4XD" or the "Company")

**Notice of Results**

**19 December, 2016** - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, will be announcing its **full year results for the year ended 31 July 2016** on Friday 6 January 2017.

Dr Clive Dix, Chief Executive Officer, and Brad Hoy, Chief Financial Officer, will host a conference call for analysts at 14.00 GMT on the day of the results. Presentation slides will be made available on the Company website before the call.

**--ENDS--**

**For further information, please contact:**

**C4X Discovery Holdings plc**

Clive Dix, Chief Executive Officer

07801 865 803

**Zeus Capital Limited**

Dan Bate

0161 831 1512

Dominic Wilson/Phil Walker

0203 829 5000

**Consilium Strategic Communications**

Mary-Jane Elliott, Matthew Neal, Melissa Gardiner

0203 709 5700

**About C4X Discovery**

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3<sup>®</sup>) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4X's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.



C4X Discovery is advancing its in-house pipeline in addiction, diabetes and inflammation with a number of new drug candidates identified and further progress made towards the clinic. In selecting new targets C4X Discovery will focus on the high-value disease areas of inflammation and neurodegeneration, and will continue to maximise value from opportunistic areas, for example, immuno-oncology.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4X to reach multiple value inflexion points since IPO. For additional information please go to: [www.c4xdiscovery.com](http://www.c4xdiscovery.com)